RY 172.93 -0.271% SHOP 157.86 0.7274% TD 75.22 0.2532% ENB 59.74 0.5216% BN 81.36 0.9429% TRI 234.42 0.5404% CNQ 43.01 1.2% CP 104.55 0.7225% CNR 146.44 0.7568% BMO 139.17 0.2377% BNS 77.04 -0.0649% CSU 4487.8101 0.7917% CM 91.94 -0.6054% MFC 44.04 1.1716% ATD 80.33 -0.5694% NGT 54.77 -0.635% TRP 66.14 0.532% SU 50.335 1.4819% WCN 245.2 -2.104% L 191.84 0.64%

Curaleaf Holdings Inc.

Healthcare CA CURA

2.135CAD
0.01(0.71%)

Last update at 2024-12-23T19:29:00Z

Day Range

2.122.20
LowHigh

52 Week Range

2.278.73
LowHigh

Fundamentals

  • Previous Close 2.12
  • Market Cap2203.43M
  • Volume209292
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA253.17M
  • Revenue TTM1357.02M
  • Revenue Per Share TTM1.84
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.39

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -167.85517M -112.59470M -77.97841M 41.31M -60.75731M
Minority interest - - - - -
Net income -379.52792M -481.81467M -258.19370M -76.67011M -89.22589M
Selling general administrative 392.79M 408.15M 373.90M 234.88M -
Selling and marketing expenses 41.99M 39.75M 41.84M 23.27M -
Gross profit 644.70M 667.70M 607.67M 142.15M 16.15M
Reconciled depreciation - - - - -
Ebit 57.88M 84.60M 73.43M -204.10982M -166.46592M
Ebitda 343.90M 300.25M 240.89M -97.19068M -117.09737M
Depreciation and amortization 286.02M 215.64M 167.45M 106.92M 49.37M
Non operating income net other - - - - -
Operating income 57.88M 84.60M 73.43M -204.10982M -166.46592M
Other operating expenses 1759.65M 1575.81M 1426.01M 1044.62M 459.73M
Interest expense 100.38M 88.84M 90.26M 69.00M 32.84M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 154.66M 232.80M 191.13M 117.43M 31.92M
Total revenue 1817.53M 1660.41M 1499.45M 840.51M 293.27M
Total operating expenses 586.82M 583.10M 534.24M 346.26M 182.62M
Cost of revenue 1172.83M 992.71M 891.78M 698.36M 277.11M
Total other income expense net -225.73380M -197.19955M -151.41329M 245.42M 105.71M
Discontinued operations - - - - -
Net income from continuing ops - - - - -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4083.15M 4626.56M 3922.17M 3013.65M 955.61M
Intangible assets 1172.44M 1213.30M 1010.01M 707.63M -
Earning assets - - - - -
Other current assets 63.55M 283.57M 147.04M 87.45M 8.40M
Total liab 2538.68M 2728.52M 1818.91M 1255.77M 432.44M
Total stockholder equity 1385.38M 1733.94M 1952.98M 1756.46M 530.06M
Deferred long term liab - - - - -
Other current liab 452.51M 451.79M 160.26M 90.74M 64.27M
Common stock - - 2811.70M 2235.12M 899.55M
Capital stock - - - - -
Retained earnings -1504.19427M -1164.65269M -618.25887M -242.15045M -172.35104M
Other liab - - - - -
Good will 826.27M 847.02M 765.26M 686.46M 89.90M
Other assets 0.00000M 0.00000M - - -
Cash 121.07M 221.10M 378.10M 93.69M 54.87M
Cash and equivalents - - - - -
Total current liabilities 651.43M 673.23M 399.46M 280.44M 137.79M
Current deferred revenue 1.14M 0.92M 175.80M 101.47M 19.60M
Net debt 1327.04M 1333.85M 645.22M 642.30M 202.03M
Short term debt 93.19M 111.06M 29.62M 28.30M 37.39M
Short long term debt - - - - -
Short long term debt total 1448.11M 1554.95M 1023.32M 736.00M 256.90M
Other stockholder equity 2905.23M 2923.78M 76.55M -6.63499M -6.75347M
Property plant equipment - - - - -
Total current assets 551.97M 884.00M 917.83M 532.36M 193.90M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 82.65M 61.22M 79.25M 40.10M 23.78M
Long term debt - - - - -
Inventory 284.70M 318.12M 313.45M 311.11M 106.86M
Accounts payable 104.59M 109.47M 33.79M 59.93M 16.52M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -15.65837M -25.19394M -317.00644M -229.87801M -190.38754M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 589.76M 673.50M 489.09M 554.76M 252.17M
Deferred long term asset charges - - - - -
Non current assets total 3531.18M 3742.55M 3004.34M 2481.30M 761.70M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments - - - - -
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities -96.07477M 54.41M 457.79M 300.55M 23.96M
Change to operating activities - - - - -
Net income -310.17831M -336.49918M -258.19370M -76.67011M -89.22589M
Change in cash -100.02546M -157.00075M 284.40M 38.83M -309.27864M
Begin period cash flow 221.10M 378.10M 93.69M 54.87M 364.14M
End period cash flow 121.07M 221.10M 378.10M 93.69M 54.87M
Total cash from operating activities 101.58M 60.41M -73.06754M 16.57M -50.84804M
Issuance of capital stock - - - - -
Depreciation 286.02M 215.64M 167.45M 106.92M 49.37M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 13.30M -20.96375M -116.75134M -123.91477M -38.14299M
Change to account receivables 0.15M -26.32348M -31.66552M 7.99M -9.21265M
Sale purchase of stock - - - -2.50800M -1.17165M
Other cashflows from financing activities -42.30594M -19.65538M -6.25236M 53.60M 32.97M
Change to netincome - - - - -
Capital expenditures 94.89M 175.29M 215.59M 169.37M 108.91M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 46.08M 85.98M -69.94950M 38.35M -18.56595M
Stock based compensation 20.01M 28.02M 39.48M 29.36M -
Other non cash items 675.60M 528.33M 597.15M 248.67M 143.73M
Free cash flow 6.69M -114.87555M -288.65313M -152.79835M -159.75315M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CURA
Curaleaf Holdings Inc.
0.01 0.71% 2.13 - 138.89 1.62 1.66 1.73 10.18
BHC
Bausch Health Companies Inc
0.06 0.56% 10.77 - 2.23 0.50 18.74 2.56 9.13
TLRY
Tilray Inc
0.29 16.29% 2.07 - 1000.00 2.17 0.36 1.69 -2.299
CRON
Cronos Group Inc
0.10 3.58% 2.89 - - 10.18 0.70 0.02 -1.9458
WEED
Canopy Growth Corp
0.10 2.60% 4.14 - - 2.77 1.22 3.58 -1.5049

Reports Covered

Stock Research & News

Profile

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.

Curaleaf Holdings Inc.

420 Lexington Avenue, New York, NY, United States, 10170

Key Executives

Name Title Year Born
Mr. Boris Alexis Jordan CEO & Chairman 1966
Mr. Joseph F. Lusardi Executive Vice-Chairman 1975
Mr. Edward Kremer Chief Financial Officer 1972
Mr. Peter Laurence Clateman J.D. Chief Legal Officer 1968
Mr. Matthew S. Darin Special Advisor NA
Mr. Camilo Russi Lyon Chief Investment Officer NA
Ms. Christine Taylor Chief Accounting Officer NA
Mr. Jakob Feinstein Manager of Investor Relations NA
Mr. James S. Shorris Chief Compliance Officer 1961
Ms. Kate Lynch Executive Vice President of Marketing NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.